Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study.

Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, Lau KP, Siu SC, Li JK, Yeung VT, Leung WY, Tong PC; SURE Study Group..

Diabetes Care. 2009 Jun;32(6):977-82. doi: 10.2337/dc08-1908.

2.

Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy.

Leung WY, So WY, Tong PC, Chan NN, Chan JC.

Am J Med. 2005 Dec;118(12):1414.

PMID:
16378791
3.

Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.

Ménard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, Ardilouze JL.

CMAJ. 2005 Dec 6;173(12):1457-66.

4.

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.

Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR.

Arch Intern Med. 2012 May 28;172(10):761-9. doi: 10.1001/archinternmed.2011.2230. Review. Erratum in: Arch Intern Med. 2012 Jul 23;172(14):1095.

5.

Analysis of metabolic parameters as predictors of risk in the RENAAL study.

Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM; RENAAL Study..

Diabetes Care. 2003 May;26(5):1402-7.

PMID:
12716796
6.

Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.

Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, Cueto-Manzano AM.

Am J Kidney Dis. 2006 Jan;47(1):78-87.

PMID:
16377388
7.

Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings.

Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, Tirino G, Pota A, Torella R, Conte G, De Nicola L.

J Hypertens. 2006 Aug;24(8):1655-61.

PMID:
16877970
8.

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group..

Diabetes Care. 2001 Jul;24(7):1167-74.

PMID:
11423497
9.

Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan.

Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T.

J Manag Care Pharm. 2012 Sep;18(7):516-26.

10.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
11.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014.

PMID:
22078152
12.

Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.

Blonde L, Woo V, Mathieu C, Yee J, Vijapurkar U, Canovatchel W, Meininger G.

Curr Med Res Opin. 2015 Nov;31(11):1993-2000. doi: 10.1185/03007995.2015.1082991.

PMID:
26373629
14.

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.

PMID:
7587846
16.

Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes.

So WY, Tong PC, Ko GT, Leung WY, Chow CC, Yeung VT, Chan WB, Critchley JA, Cockram CS, Chan JC.

Am J Manag Care. 2003 Sep;9(9):606-15.

18.

Prospective study on renal outcome of IgA nephropathy superimposed on diabetic glomerulosclerosis in type 2 diabetic patients.

Mak SK, Wong PN, Lo KY, Tong GM, Wong AK.

Nephrol Dial Transplant. 2001 Jun;16(6):1183-8.

19.

Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.

Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, Sambataro M, Piarulli F, Sfriso A, Nosadini R.

J Nephrol. 2001 Nov-Dec;14(6):461-71.

PMID:
11783602
20.

Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study.

Orchard TJ, Forrest KY, Kuller LH, Becker DJ; Pittsburgh Epidemiology of Diabetes Complications Study..

Diabetes Care. 2001 Jun;24(6):1053-9.

PMID:
11375370
Items per page

Supplemental Content

Support Center